Neogen (DE:NG2)
NASDAQ:NG2
Earnings Data
Report Date
Jul 28, 2026Before Open (Confirmed)
Period Ending
2026 (Q4)Consensus EPS Forecast
0.05Last Year’s EPS
-2.45Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call presented a balanced picture: solid execution and margin improvement in Food Safety, positive free cash flow, progress on the Petrifilm manufacturing transition, and a clear multi-pronged transformation plan. However, notable near-term challenges remain—most prominently supplier-related disruptions in Animal Safety, logistics/freight inflation, FX headwinds, inventory legacy risks and a still-elevated debt position. Management is taking concrete actions (supplier qualification, operational centralization, targeted CapEx and a planned divestiture) that support medium-term improvement, but near-term headwinds temper upside.Company Guidance
Third Quarter Revenue and Core Growth
Q3 revenue of $211.2 million with core revenue growth of +0.1% year-over-year; demonstrates stability in a mixed market environment.
Food Safety Segment Strength
Food Safety revenue of $156.7 million, delivering 4% core growth year-over-year; led by indicator testing (+11%) and strong pathogen test kit performance.
Improved Profitability Metrics
Adjusted EBITDA of $48.2 million with a margin of 22.8%, an improvement of ~110 basis points sequentially; adjusted gross margin of 51.7% and reported gross margin of 46.9% (essentially flat year-over-year excluding one-time costs).
Positive Free Cash Flow and Balance Sheet Actions
Free cash flow in Q3 was $11.1 million and free cash flow is positive year-to-date; announced sale of genomics business for $160 million (expected net proceeds ~$140M) to reduce debt and target net debt/adjusted EBITDA below 3x by end of 2026.
Petrifilm Manufacturing Transition Progress
On-schedule transition with full validation completed for 100% of production equipment and SKU validations underway; in-house manufacturing expected to improve contribution margin on incremental Petrifilm revenue and enable custom SKUs and R&D prototyping (research-scale R&D line funded Q4 FY26).
Cost Discipline and Operating Expense Improvement
Adjusted operating expenses declined ~9% sequentially versus Q2, driven by cost control and restructuring actions; company emphasizing further OpEx scrutiny and investments targeted at value-creating transformation.
Strategic Transformation Initiatives
Clear transformation plan: (1) commercial prowess (new global commercial leadership and solutions-based selling), (2) high-impact innovation (organic and licensed tech, Petrifilm SKU expansion), and (3) operational efficiency (S&OP, AI-enabled planning, supplier controls).
Market Dynamics Supporting Long-Term Demand
Industry recall activity rose ~15% from 2024 to 2025 and FDA recalled volume more than doubled year-over-year, reinforcing structural demand for reliable food-safety solutions and Neogen's market relevance.
DE:NG2 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DE:NG2 Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 09, 2026 | €8.52 | €8.76 | +2.86% |
Jan 08, 2026 | €6.25 | €6.30 | +0.80% |
Oct 09, 2025 | €4.78 | €4.98 | +4.21% |
Jul 29, 2025 | €4.46 | €4.66 | +4.48% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Neogen (DE:NG2) report earnings?
Neogen (DE:NG2) is schdueled to report earning on Jul 28, 2026, Before Open (Confirmed).
What is Neogen (DE:NG2) earnings time?
Neogen (DE:NG2) earnings time is at Jul 28, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Neogen stock?
The P/E ratio of Neogen is N/A.
What is DE:NG2 EPS forecast?
DE:NG2 EPS forecast for the fiscal quarter 2026 (Q4) is 0.05.